JP5814467B2 - キナーゼ阻害剤としてのイミダゾ［１，２−ｂ］ピリダジン誘導体 - Google Patents

キナーゼ阻害剤としてのイミダゾ［１，２−ｂ］ピリダジン誘導体 Download PDF

Info

Publication number
JP5814467B2
JP5814467B2 JP2014519977A JP2014519977A JP5814467B2 JP 5814467 B2 JP5814467 B2 JP 5814467B2 JP 2014519977 A JP2014519977 A JP 2014519977A JP 2014519977 A JP2014519977 A JP 2014519977A JP 5814467 B2 JP5814467 B2 JP 5814467B2
Authority
JP
Japan
Prior art keywords
group
compound
imidazo
phenyl
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014519977A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2013183578A1 (ja
Inventor
泰幸 武田
泰幸 武田
謙次 吉川
謙次 吉川
佳子 神子島
佳子 神子島
裕子 山本
裕子 山本
亮一 田中
亮一 田中
裕一 冨永
裕一 冨永
真基 木我
真基 木我
義人 浜田
義人 浜田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Sankyo Co Ltd
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Priority to JP2014519977A priority Critical patent/JP5814467B2/ja
Application granted granted Critical
Publication of JP5814467B2 publication Critical patent/JP5814467B2/ja
Publication of JPWO2013183578A1 publication Critical patent/JPWO2013183578A1/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2014519977A 2012-06-04 2013-06-03 キナーゼ阻害剤としてのイミダゾ［１，２−ｂ］ピリダジン誘導体 Active JP5814467B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2014519977A JP5814467B2 (ja) 2012-06-04 2013-06-03 キナーゼ阻害剤としてのイミダゾ［１，２−ｂ］ピリダジン誘導体

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2012127079 2012-06-04
JP2012127079 2012-06-04
JP2014519977A JP5814467B2 (ja) 2012-06-04 2013-06-03 キナーゼ阻害剤としてのイミダゾ［１，２−ｂ］ピリダジン誘導体
PCT/JP2013/065328 WO2013183578A1 (ja) 2012-06-04 2013-06-03 キナーゼ阻害剤としてのイミダゾ[１，２－ｂ]ピリダジン誘導体

Publications (2)

Publication Number Publication Date
JP5814467B2 true JP5814467B2 (ja) 2015-11-17
JPWO2013183578A1 JPWO2013183578A1 (ja) 2016-01-28

Family

ID=49711970

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014519977A Active JP5814467B2 (ja) 2012-06-04 2013-06-03 キナーゼ阻害剤としてのイミダゾ［１，２−ｂ］ピリダジン誘導体

Country Status (32)

Country Link
US (2) US9187489B2 (Direct)
EP (1) EP2857404B1 (Direct)
JP (1) JP5814467B2 (Direct)
KR (1) KR101781255B1 (Direct)
CN (1) CN104520300B (Direct)
AU (1) AU2013272701B2 (Direct)
BR (1) BR112014029851B1 (Direct)
CA (1) CA2874819C (Direct)
CO (1) CO7160119A2 (Direct)
CY (1) CY1119607T1 (Direct)
DK (1) DK2857404T3 (Direct)
ES (1) ES2648228T3 (Direct)
HR (1) HRP20171724T1 (Direct)
HU (1) HUE037221T2 (Direct)
IL (1) IL236075A (Direct)
IN (1) IN2014MN02497A (Direct)
LT (1) LT2857404T (Direct)
MX (1) MX357021B (Direct)
MY (1) MY170326A (Direct)
NO (1) NO2857404T3 (Direct)
NZ (1) NZ702574A (Direct)
PH (1) PH12014502721A1 (Direct)
PL (1) PL2857404T3 (Direct)
PT (1) PT2857404T (Direct)
RS (1) RS56625B1 (Direct)
RU (1) RU2635917C2 (Direct)
SG (1) SG11201408052WA (Direct)
SI (1) SI2857404T1 (Direct)
SM (1) SMT201700539T1 (Direct)
TW (1) TWI585088B (Direct)
WO (1) WO2013183578A1 (Direct)
ZA (1) ZA201408843B (Direct)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS53350B (sr) 2008-09-22 2014-10-31 Array Biopharma, Inc. Supstituisana jedinjenja imidazo[1,2-b]piridazina kao inhibitori trk kinaze
EP2350071B1 (en) 2008-10-22 2014-01-08 Array Biopharma, Inc. SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
PL3205654T3 (pl) 2010-05-20 2019-08-30 Array Biopharma, Inc. Związki makrocykliczne jako inhibitory kinazy TRK
AU2013268400B2 (en) 2012-05-30 2017-07-13 Nippon Shinyaku Co., Ltd. Aromatic heterocyclic derivative and pharmaceutical
AU2015238298B2 (en) * 2014-03-27 2019-04-18 Janssen Pharmaceutica Nv Substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrimidine derivatives and 2,3-dihydro-1H-imidazo[1,2-b]pyrazole derivatives as ROS1 inhibitors
JP6522646B2 (ja) * 2014-03-27 2019-05-29 ヤンセン ファーマシューティカ エヌ．ベー． ＲＯＳ１阻害剤としての置換４，５，６，７−テトラヒドロ−ピラゾロ［１，５−α］ピラジン誘導体および５，６，７，８−テトラヒドロ−４Ｈ−ピラゾロ［１，５−α］［１，４］ジアゼピン誘導体
MX375716B (es) * 2014-04-25 2025-03-06 Exelixis Inc Método para tratar adenocarcinoma de pulmón.
CN107428760B (zh) 2014-11-16 2021-04-27 阵列生物制药公司 (s)-n-(5-((r)-2-(2,5-二氟苯基)-吡咯烷-1-基)-吡唑并[1,5-a]嘧啶-3-基)-3-羟基吡咯烷-1-甲酰胺硫酸氢盐的晶型
PE20180329A1 (es) 2015-06-01 2018-02-13 Loxo Oncology Inc Metodos para diagnosticar y tratar el cancer
ES2849951T3 (es) 2015-06-18 2021-08-24 89Bio Ltd Derivados de piperidina 4-bencil y 4-benzoil sustituidos
EA201890086A1 (ru) 2015-06-18 2018-06-29 Сефалон, Инк. 1,4-замещенные производные пиперидина
BR112018000808A2 (pt) 2015-07-16 2018-09-04 Array Biopharma Inc compostos de pirazolo[1,5-a]piridina substituída como inibidores de ret cinase
BR112018008357A2 (en) 2015-10-26 2018-11-27 Loxo Oncology, Inc. dot mutations in trk inhibitor resistant cancer and related methods
CN106854174A (zh) * 2015-12-08 2017-06-16 湖南华腾制药有限公司 一种4位取代哌啶衍生物的制备方法
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
FI3439662T3 (fi) 2016-04-04 2024-09-04 Loxo Oncology Inc (s)-n-(5-((r)-2-(2,5-difluorifenyyli)pyrrolidin-1-yyli)pyratsolo[1,5-a]pyrimidin-3-yyli)-3-hydroksipyrrolidiini-1-karboksamidin nesteformulaatioita
RS65988B1 (sr) 2016-04-04 2024-10-31 Loxo Oncology Inc Postupak lečenja pedijatrijskih karcinoma
HRP20201984T1 (hr) 2016-05-18 2021-04-16 Loxo Oncology, Inc. Priprema (s)-n-(5-((r)-2-(2,5-difluorofenil)pirolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-3-hidroksipirolidin-1-karboksamida
CN107400082A (zh) * 2016-05-19 2017-11-28 湖南华腾制药有限公司 一种取代哌啶衍生物的制备方法
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JOP20190072A1 (ar) * 2016-10-13 2019-04-07 Glaxosmithkline Ip Dev Ltd مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدم
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
WO2018136661A1 (en) 2017-01-18 2018-07-26 Andrews Steven W SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
HRP20230764T1 (hr) * 2017-03-14 2023-10-13 Daiichi Sankyo Company, Limited POSTUPAK ZA PROIZVODNJU DERIVATA 3, 6-DISUPSTITUIRANOG IMIDAZOL[1, 2-b]PIRIDAZINA
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
US10180422B1 (en) 2017-08-22 2019-01-15 Scripps Health Methods of treating a neuroendocrine tumor
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
TWI876442B (zh) 2017-10-10 2025-03-11 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
CA3080157A1 (en) 2017-10-26 2019-05-02 Array Biopharma Inc. Formulations of a macrocyclic trk kinase inhibitor
CN109748902B (zh) * 2017-11-02 2020-11-06 杭州科巢生物科技有限公司 一种盐酸安罗替尼的制备方法
KR102078775B1 (ko) 2017-11-29 2020-02-19 서울대학교산학협력단 항-ros1 항체 및 그의 용도
CN108129288B (zh) * 2017-12-27 2021-01-22 上海毕得医药科技股份有限公司 一种反式-3-羟基环丁基甲酸的合成方法
CN111630054B (zh) 2018-01-18 2023-05-09 奥瑞生物药品公司 作为RET激酶抑制剂的取代的吡唑并[3,4-d]嘧啶化合物
WO2019143977A1 (en) 2018-01-18 2019-07-25 Array Biopharma Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
TW201932464A (zh) 2018-01-18 2019-08-16 美商亞雷生物製藥股份有限公司 作為ret激酶抑制劑之經取代吡唑基[4,3-c]吡啶化合物
US20210023086A1 (en) 2018-03-29 2021-01-28 Loxo Oncology, Inc. Treatment of trk-associated cancers
EA202190342A1 (ru) 2018-07-24 2021-07-22 Тайхо Фармасьютикал Ко., Лтд. Гетеробициклические соединения для ингибирования активности shp2
KR102612513B1 (ko) 2018-07-31 2023-12-12 록쏘 온콜로지, 인코포레이티드 (s)-5-아미노-3-(4-((5-플루오로-2-메톡시벤즈아미도)메틸)페닐)-1-(1,1,1-트리플루오로프로판-2-일)-1h-피라졸-4-카르복스아미드의 분무-건조된 분산물 및 제제
WO2020055672A1 (en) 2018-09-10 2020-03-19 Array Biopharma Inc. Fused heterocyclic compounds as ret kinase inhibitors
EP3898615A1 (en) 2018-12-19 2021-10-27 Array Biopharma, Inc. 7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer
EP3898626A1 (en) 2018-12-19 2021-10-27 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases
CN113543852A (zh) * 2019-03-06 2021-10-22 第一三共株式会社 吡咯并吡唑衍生物
BR112021018168B1 (pt) 2019-03-21 2023-11-28 Onxeo Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer
KR102731401B1 (ko) 2019-05-08 2024-11-15 티와이케이 메디슨즈, 인코포레이티드 키나아제 억제제로 사용되는 화합물 및 이의 응용
GB201911928D0 (en) 2019-08-20 2019-10-02 Otsuka Pharma Co Ltd Pharmaceutical compounds
US20220401436A1 (en) 2019-11-08 2022-12-22 INSERM (Institute National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
TW202200589A (zh) * 2020-05-28 2022-01-01 瑞士商諾華公司 Ｍｌｌ１抑制劑及抗癌劑
CN114957259A (zh) * 2021-02-25 2022-08-30 南京明德新药研发有限公司 氰基取代的芳香双环类化合物及其应用
EP4363420A4 (en) * 2021-07-01 2025-06-11 Anheart Therapeutics (Hangzhou) Co., Ltd. Crystalline forms of 3-{4-[(2r)-2-aminopropoxy]phenyl}-n-[(1r)- 1-(3-fluorophenyl) ethyl]imidazo[1,2-b]pyridazin-6-amine and salts thereof
IL316837A (en) * 2022-05-18 2025-01-01 Anheart Therapeutics Hangzhou Co Ltd METHOD FOR PRODUCING 3,6-DISUPTATED-IMIDAZO[1,2-B]PYRIDAZINE COMPOUNDS
CN114989176B (zh) * 2022-07-08 2024-08-27 深圳市新樾生物科技有限公司 咪唑并哒嗪类衍生物及其应用
CN115197115B (zh) * 2022-08-25 2024-11-08 成都金博汇康医药科技有限公司 一种手性5-氧代吡咯烷-3-甲酸的制备方法与应用
EP4585598A1 (en) 2022-09-07 2025-07-16 Suzhou Langrui Biopharmaceutical Co., Ltd. Macrocyclic imidazo[1,2-b]pyridazine derivative, preparation method therefor, and use thereof
CN117659020A (zh) * 2022-09-07 2024-03-08 苏州朗睿生物医药有限公司 一种咪唑并[1,2-b]哒嗪衍生物及其制备方法和用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6399780B1 (en) 1999-08-20 2002-06-04 Cephalon, Inc. Isomeric fused pyrrolocarbazoles and isoindolones
WO2002020479A1 (en) 2000-09-01 2002-03-14 Glaxo Group Limited Substituted oxindole derivatives as tyrosine kinase inhibitors
EP1317446A1 (en) 2000-09-01 2003-06-11 Glaxo Group Limited Oxindole derivatives
JP2003231687A (ja) 2002-02-04 2003-08-19 Japan Tobacco Inc ピラゾリル縮合環化合物及びその医薬用途
MY141220A (en) 2003-11-17 2010-03-31 Astrazeneca Ab Pyrazole derivatives as inhibitors of receptor tyrosine kinases
JP2007533717A (ja) 2004-04-21 2007-11-22 アストラゼネカ アクチボラグ 化合物
WO2006070943A1 (ja) * 2004-12-28 2006-07-06 Takeda Pharmaceutical Company Limited 縮合イミダゾール化合物およびその用途
NZ561145A (en) 2005-02-04 2011-02-25 Astrazeneca Ab Pyrazolylaminopyridine derivatives useful as kinase inhibitors
AU2006215386B2 (en) 2005-02-16 2009-06-11 Astrazeneca Ab Chemical compounds
CA2598076A1 (en) 2005-02-16 2006-08-24 Astrazeneca Ab Chemical compounds
JP2009502734A (ja) 2005-07-29 2009-01-29 アステラス製薬株式会社 Ｌｃｋ阻害剤としての縮合複素環
US7776878B2 (en) * 2005-08-01 2010-08-17 Hoffmann-La Roche Inc. Heterocyclic benzylamino derivatives, their manufacture and use as pharmaceutical agents
DE102005042742A1 (de) 2005-09-02 2007-03-08 Schering Ag Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
DE102006029447A1 (de) * 2006-06-21 2007-12-27 Bayer Schering Pharma Ag Oxo-substituierte Imidazo[1,2b]pyridazine, deren Herstellung und Verwendung als Arzneimittel
RU2009120389A (ru) * 2006-10-30 2010-12-10 Новартис АГ (CH) Гетероциклические соединения в качестве противовоспалительных агентов
WO2008058126A2 (en) 2006-11-06 2008-05-15 Supergen, Inc. Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
WO2008072682A1 (ja) * 2006-12-15 2008-06-19 Daiichi Sankyo Company, Limited イミダゾ［１，２－ｂ］ピリダジン誘導体
JP2009227599A (ja) * 2008-03-21 2009-10-08 Daiichi Sankyo Co Ltd イミダゾピリダジン誘導体
KR101324804B1 (ko) 2008-05-13 2013-11-01 아이알엠 엘엘씨 키나제 억제제로서의 질소 함유 융합 헤테로사이클 및 그의 조성물
RS53350B (sr) * 2008-09-22 2014-10-31 Array Biopharma, Inc. Supstituisana jedinjenja imidazo[1,2-b]piridazina kao inhibitori trk kinaze
KR101147550B1 (ko) * 2009-10-22 2012-05-17 한국과학기술연구원 단백질 키나아제 저해활성을 가지는 2,7-치환된 티에노［3,2-ｄ］피리미딘 화합물
JPWO2012005299A1 (ja) 2010-07-07 2013-09-05 日本新薬株式会社 Ｒｏｓチロシンキナーゼ阻害剤
WO2012125667A1 (en) 2011-03-17 2012-09-20 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF

Also Published As

Publication number Publication date
AU2013272701A1 (en) 2015-01-15
IL236075A (en) 2017-10-31
CO7160119A2 (es) 2015-01-15
TW201400486A (zh) 2014-01-01
DK2857404T3 (en) 2017-12-04
PH12014502721B1 (en) 2015-02-02
HK1207374A1 (en) 2016-01-29
MY170326A (en) 2019-07-17
AU2013272701A2 (en) 2015-01-22
NZ702574A (en) 2016-07-29
CA2874819C (en) 2017-06-20
HUE037221T2 (hu) 2018-08-28
US20160046639A1 (en) 2016-02-18
IN2014MN02497A (Direct) 2015-07-17
CN104520300B (zh) 2016-12-21
EP2857404B1 (en) 2017-08-23
JPWO2013183578A1 (ja) 2016-01-28
US9751887B2 (en) 2017-09-05
RS56625B1 (sr) 2018-03-30
EP2857404A1 (en) 2015-04-08
US20150051190A1 (en) 2015-02-19
LT2857404T (lt) 2017-11-10
KR20150014942A (ko) 2015-02-09
ES2648228T3 (es) 2017-12-29
SI2857404T1 (sl) 2017-11-30
BR112014029851A2 (pt) 2017-06-27
ZA201408843B (en) 2016-01-27
RU2635917C2 (ru) 2017-11-17
RU2014153627A (ru) 2016-08-10
KR101781255B1 (ko) 2017-09-22
AU2013272701B2 (en) 2017-12-21
WO2013183578A1 (ja) 2013-12-12
MX2014014803A (es) 2015-02-12
SG11201408052WA (en) 2015-01-29
BR112014029851B1 (pt) 2023-01-03
PH12014502721A1 (en) 2015-02-02
SMT201700539T1 (it) 2018-01-11
EP2857404A4 (en) 2016-01-20
PL2857404T3 (pl) 2018-04-30
US9187489B2 (en) 2015-11-17
IL236075A0 (en) 2015-02-01
CY1119607T1 (el) 2018-04-04
PT2857404T (pt) 2017-11-23
MX357021B (es) 2018-06-25
CA2874819A1 (en) 2013-12-12
CN104520300A (zh) 2015-04-15
HRP20171724T1 (hr) 2018-01-12
TWI585088B (zh) 2017-06-01
NO2857404T3 (Direct) 2018-01-20

Similar Documents

Publication Publication Date Title
JP5814467B2 (ja) キナーゼ阻害剤としてのイミダゾ［１，２−ｂ］ピリダジン誘導体
JP7033764B2 (ja) Ｃｄｋ阻害剤としての置換型ヘテロシクリル誘導体
JP6494622B2 (ja) カゼインキナーゼ１ｄ／ｅ阻害剤としての置換された４，５，６，７−テトラヒドロピラゾロ［１，５−ａ］ピラジン誘導体
JP6267231B2 (ja) カゼインキナーゼ１δ／ε阻害剤としての新規な置換イミダゾール
JP7723666B2 (ja) 環式化合物およびその使用方法
JP7549597B2 (ja) Ｅｅｄおよびｐｒｃ２調節物質としての大環状アゾロピリジン誘導体
EP4389738A1 (en) Sos1 inhibitor and use thereof
EP3694331B1 (en) Indazolyl-spiro[2.3]hexane-carbonitrile derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
EP3601264A1 (en) Bruton's tyrosine kinase inhibitors
CA3137611A1 (en) 4h-pyrrolo[3,2-c]pyridin-4-one derivatives
WO2015125785A1 (ja) 複数置換基を有するピラゾロン誘導体
JP2020525469A (ja) 新規キノリノン化合物
EP4141003A1 (en) Pyrazolo[1,5-a]pyridine derivative, preparation method therefor, and composition and use thereof
JP2016056133A (ja) 環状構造側鎖を有するピラゾロン誘導体
HK1207374B (en) Imidazo[1,2-b]pyridazine derivatives as kinase inhibitors
HK1233627A (en) Serine/threonine kinase inhibitors
HK1233627A1 (en) Serine/threonine kinase inhibitors

Legal Events

Date Code Title Description
A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20150907

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150914

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150917

R150 Certificate of patent or registration of utility model

Ref document number: 5814467

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250